Regeneron, Guardant Health, and Sturm Ruger See High Options Volume
Among the components of the Russell 3000 index, notable options trading activity was observed today in Regeneron Pharmaceuticals, Inc. (Symbol: REGN). A total of 10,842 contracts have exchanged hands, equating to approximately 1.1 million underlying shares. This represents about 90.4% of REGN’s average daily trading volume over the past month, which stands at 1.2 million shares. The $500 strike put option, expiring June 20, 2025, experienced particularly heavy trading, with 2,953 contracts traded, corresponding to roughly 295,300 underlying shares of REGN. Below is a chart showing REGN’s trailing twelve-month trading history, with the $500 strike highlighted in orange:
Guardant Health Inc (Symbol: GH) also garnered significant options trading volume today, with 11,389 contracts traded. This translates to approximately 1.1 million underlying shares, or about 58.3% of GH’s average daily trading volume of 2.0 million shares over the past month. The $55 strike call option expiring May 16, 2025, showed particularly high activity, with 2,463 contracts traded, representing around 246,300 underlying shares of GH. Below is a chart depicting GH’s trailing twelve-month trading history, with the $55 strike highlighted in orange:
Sturm, Ruger & Co., Inc. (Symbol: RGR) recorded options trading volume of 767 contracts, equating to approximately 76,700 underlying shares. This represents around 57.2% of RGR’s average daily trading volume over the past month of 134,010 shares. The $45 strike call option expiring May 16, 2025, saw high volume with 731 contracts traded, which corresponds to about 73,100 underlying shares of RGR. Below is a chart illustrating RGR’s trailing twelve-month trading history, with the $45 strike highlighted in orange:
For details regarding the available expirations for REGN, GH, or RGR options, consult StockOptionsChannel.com.
Today’s Most Active Call & Put Options of the S&P 500 »
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
